Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.

Slides:

Advertisements

Similar presentations

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Advertisements

Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma Vinita.

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

DNA Methyltransferase-1 (DNMT1): A Flow Cytometric Pharmacodynamic Assay for Azacitidine Hypomethylating Therapy after Allogeneic Hematopoietic Stem Cell.

Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation Navneet S. Majhail, MD, MS, Tejo.

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic.

How to Treat MDS without Stem Cell Transplantation

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Allogeneic Stem Cell Transplantation in Myelofibrosis

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Vancomycin-Resistant Enterococcus (VRE) Colonization and Blood Stream Infection (BSI): Prevalence, Risk Factors, and Impact on Early Clinical Outcomes.

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner,

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Biology of Blood and Marrow Transplantation

Peritransplant Use of Ultraviolet-B Irradiation (UV-B) Therapy Is Detrimental to Allogeneic Stem Cell Transplantation Outcome Meltem Yüksel, Elma Baron,

Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,

Access to Hematopoietic Cell Transplantation in the United States

Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia

Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia Reinhold Munker, Ruta Brazauskas, Hai Lin Wang, Marcos.

David C. Yao, MD, PhD, Paolo Caimi, MD, Hillard M

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia Hien K. Duong, MD, Mojtaba Akhtari, MD, Kwang Woo Ahn, PhD, Zhen-Huan.

Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Extranodal Natural Killer (Nk)/T-Cell Lymphoma, Nasal Type (ENKL): A CIBMTR Analysis Abraham.

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children Predicts Improved Survival Ashok Srinivasan, William Mitchell,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Estimating Propensity Scores for the Receipt of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Outcomes Research Using Claims Data: A Machine.

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Low-Dose Azacitidine (AZA) for Treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapse after Allogeneic Hematopoietic Cell.

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.

Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Infection Prevention - Visitors and the Best of Intentions

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation? Melhem.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Early Response to Initial Induction Chemotherapy in Acute Myeloid Leukemia (AML) and Outcomes after Allogeneic Hematopoietic Cell Transplant (HCT) Masumi.

The Role for Induction Chemotherapy and Allogeneic Stem Cell Transplant in Patients with Chronic Myelomonocytic Leukemia That Have Undergone Leukemic.

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

Gerard Socié, K. Scott Baker, Smita Bhatia

Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation Carlos A. Ramos, Rima.

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study Simrit Parmar,

Heather A. Himburg, PhD, Liman Zhao, Jenny Kan, John P. Chute, M.D.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Optimization of Anti-Thymocyte Globulin Administration Schedule in Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation

Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia SungNam Lim, Je-Hwan Lee, MD, PhD,

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation Daniel R Couriel,

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

Presentation transcript:

Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia (CLL) Carlos H. Silva Rondon, MD, Thomas Whitton, Basem M. William, MD, Stan L. Gerson, MD, Brenda Cooper, MD, Hillard M. Lazarus, MD, Marcos de Lima, MD, Paolo Caimi, MD Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S210-S211 (March 2016) DOI: 10.1016/j.bbmt.2015.11.606 Copyright © 2016 Terms and Conditions

Figure 1 Overall survival after alloHCT and chemotherapy Lines 1-4. Biology of Blood and Marrow Transplantation 2016 22, S210-S211DOI: (10.1016/j.bbmt.2015.11.606) Copyright © 2016 Terms and Conditions

Figure 2 Time to next therapy after alloHCT and chemotherapy lines 1-4, with death accounted as competing risk. Biology of Blood and Marrow Transplantation 2016 22, S210-S211DOI: (10.1016/j.bbmt.2015.11.606) Copyright © 2016 Terms and Conditions